Time filter

Source Type

Sanathnagar, India

Kishore M.,College and Research center | Jayaprakash M.,Natco Research Center | Vijayabhaskarareddy T.,Dr Reddys Laboratories
International Journal of ChemTech Research | Year: 2011

Rapid, simple and sensitive spectrophotometric methods are presented for the determination of Capecitabine. The methods are based on their oxidation and precipitation reactions. In both methods the reactions can be monitored spectrophotometrically by measuring the absorbance of the produced complexes at 520 and 560 nm. The proposed methods have permitted the quantification of Capecitabine over linearity in the range of 10-120 mg/ml and its percentage recovery was found to be 99.65-99.93 %. Source

Bhujanga Rao A.K.S.,Natco Research Center
Asian Journal of Pharmaceutical and Clinical Research | Year: 2012

A series of N-substituted-5-methyl-1-(4-methylphenyl)-1H-1,2,3-triazole-4-carboxamide derivatives were synthesized by treating 5-methyl-1-(4-methylphenyl)-1H-1,2,3-triazole-4-carboxylic acid with thionyl chloride followed by reaction with various amines. IR, 1H NMR spectra and mass spectral data are confirming the synthesis of N-substituted-5-methyl-1-(4-methylphenyl)-1H-1, 2, 3-triazole-4-carboxamide derivatives. Source

Amala K.,Natco Research Center | Bhujanga R.A.K.S.,Natco Research Center | Dubey P.K.,Jawaharlal Nehru Technological University
Asian Journal of Pharmaceutical and Clinical Research | Year: 2011

Chronic Myelogenous Leukemia (CML) and Philadelphia chromosome positive (Ph+) Acute Lymphoblastic Leukemia (ALL) are caused by the BCR-ABL oncogene. Imatinib inhibits the tyrosine kinase activity of the BCR-ABL protein and is an effective, frontline therapy for chronic-phase CML. However, accelerated or blast-crisis phase CML patients and Ph+ ALL patients often relapse due to drug resistance resulting from the emergence of imatinib-resistant point mutations within the BCR-ABL tyrosine kinase domain. This has stimulated the development of new kinase inhibitors that are able to over-ride resistance to Imatinib. The novel BCR-ABL inhibitor, AN-024, was designed to fit into the ATP-binding site of the BCR-ABL protein with higher affinity than Imatinib. In addition to being more potent than Imatinib (IC50<1 nM) against wild-type BCR-ABL, AN-024 is also significantly active against Imatinib-resistant BCR-ABL mutants. In preclinical studies, AN-024 demonstrated activity in vitro and in vivo against wild-type and Imatinib-resistant BCR-ABL expressing cells. Source

Parvataneni D.M.,Natco Research Center | Devraj R.,Natco Research Center | Mangamoori L.N.,Jawaharlal Nehru Technological University
Journal of Microencapsulation | Year: 2013

Surfactants are routinely included in tablets during wet or dry granulations or along with directly compressible vehicles to improve wetting, disintegration and dissolution. Besides this micellar solubilization can improve permeability of poorly soluble drugs via gastrointestinal tract membranes thereby enhancing oral bioavailability. Microparticle-entrapped micelles (MEM) technology is a novel method of incorporating surfactants in tablets for improving in vitro and in vivo performance of poorly water-soluble drugs. Valsartan (VAL) was solubilized in cremophor EL micelles at cloud point temperature; lactose was dissolved in micellar dispersion and the dispersion was directly spray-dried to obtain solid product, which was subsequently converted into tablets using suitable excipients. VAL tablets produced by applying MEM technology improved dissolution performance of valsartan tablets. These tablets exhibited superior dissolution rate over controls and marketed tablets in all media employed irrespective of pH conditions and composition. © 2013 Informa UK Ltd. Source

Shrivastava A.,Natco Research Center | Durga Prasad K.,Natco Research Center | Giri A.,Jawaharlal Nehru Technological University
International Journal of Pharmacy and Technology | Year: 2012

In this study we have made an attempt to find relationship between molecular docking scoring function and the IC 50 inhibitory potency. For this work we have performed Insilico docking studies of five known PI3K inhibitors-GDC- 0941, GDC-0980, GSK2146458, BKM-120 and CHN-517385 on PI3K gamma crystal Structure using software Ligandfit and Autodock. This prediction may help in structure based drug design studies and in selection of designed analogues. Source

Discover hidden collaborations